Welcome to our dedicated page for ADMS news (Ticker: ADMS), a resource for investors and traders seeking the latest updates and insights on ADMS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ADMS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ADMS's position in the market.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced that CEO Neil F. McFarlane will participate in a fireside chat at the William Blair Biotech Focus Conference 2021 on July 15, 2021, at 1:00 PM ET. This event, which will focus on the company's dedication to neurological disease treatments, will be broadcast live from the investor relations section of the Adamas website. Replays will be available for 30 days post-event. Adamas aims to deliver innovative therapies to alleviate the burden of neurological diseases.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced it will present at the SVB Leerink CNS Forum on June 29th at 1:10 pm ET, discussing "What’s Happening in Parkinson’s Disease & the GOCOVRI Opportunity." This presentation will be live-streamed from the company's investor relations website. Interested parties can access replays of the event for 30 days following the presentation. Adamas is dedicated to developing innovative treatments for neurological diseases, aiming to lessen the burden on patients and caregivers.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced the granting of 22,500 restricted stock units to three new employees. These units will vest over three years and were issued under the 2016 Inducement Plan, approved by the board in March 2016. This initiative aims to attract talent to support the company's vision of delivering innovative treatments for neurological diseases.
Adamas is committed to developing therapies that alleviate the impact of neurological disorders on patients and the broader society.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced a new publication in the journal Neurology and Therapy detailing a post-hoc analysis of GOCOVRI® (amantadine) in treating motor symptoms in Parkinson’s disease (PD). The analysis, based on two Phase 3 trials with 196 patients, shows significant improvements in daily activities impacted by PD symptoms. Key findings include 53.8% of patients improving from freezing of gait and 66.7% improving from tremors after 12 weeks of GOCOVRI treatment. The results support GOCOVRI's role in managing PD complications.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) will participate in two key conferences in June 2021. Chief Financial Officer Christopher B. Prentiss will present at the William Blair 41st Annual Growth Stock Conference on June 3 at 11:00 am ET. CEO Neil F. McFarlane will engage in a fireside chat at the JMP Securities Life Sciences Conference on June 16 at 3:30 pm ET. Both events will be streamed live on Adamas' investor relations website and replays will be available for 30 days.
Adamas Pharmaceuticals reported Q1 2021 revenues of $19.3 million, a 33% increase from Q1 2020. GOCOVRI sales were $17.7 million, showing a 22% rise. The number of total paid prescriptions for GOCOVRI increased by 21%, indicating strong market demand. Although the company posted a net loss of $12.6 million, this was improved from a $16.6 million loss in the prior year. Cash position strengthened to $127.4 million, up from $83.4 million in December 2020. Looking ahead, Adamas maintains guidance on R&D and SG&A expenses for 2021.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) has announced the granting of restricted stock units (RSUs) to five new employees, totaling 58,500 shares. These RSUs will vest over a period of three years, as per the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was established to attract new talent. This move reflects the company's commitment to incentivizing and retaining skilled professionals to enhance its focus on developing innovative treatments for neurological diseases.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced that CEO Neil F. McFarlane will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021, at 11:45 am ET. The session will be available via live webcast on the company's investor relations website, with a replay accessible for 30 days. Adamas Pharmaceuticals aims to deliver innovative treatments for neurological diseases, focusing on reducing the burden on patients and caregivers. For further information, visit www.adamaspharma.com.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) will report its first quarter 2021 financial results on May 10, 2021, after the market closes. The company will host a conference call and webcast at 4:30 p.m. ET to discuss these results and provide a corporate update. Participants can access the call by dialing 1-877-407-9716 (U.S./Canada) or 1-201-493-6779 (international) using Conference ID: 13718098. The live webcast will be accessible through the investor section of the Adamas website and available for replay for approximately 30 days.
